CJC-1295 and albumin
The chemical attachment is an achievement I can admire. The health claims need their own hearing.
Stations
A larger travelling companion
CJC-1295 starts with the active first twenty-nine residues of growth-hormone-releasing hormone. Four amino-acid substitutions protect that scaffold against breakdown. In the long-acting DAC form, a chemical handle also bonds covalently to albumin, the abundant protein in blood. The original design experiments tested that albumin attachment in rats and in vitro.
This is an ingenious use of something already circulating in the body. The peptide gains time by attaching to a much larger companion. The review of GHRH and its analogues supplies the wider receptor and pharmacology context: stimulation of the pituitary raises growth hormone, which in turn raises IGF-1.
“CJC-1295 no DAC” usually refers to Modified GRF 1-29, which lacks the albumin-binding handle and is short-acting. That missing attachment changes the exposure substantially. I regard the DAC suffix as essential information whenever a hormone result is being discussed.
Healthy volunteer hormone assays
In the healthy-adult pharmacology study, mean growth hormone rose two- to ten-fold for six days or more, while IGF-1 rose one-and-a-half to three-fold for nine to eleven days. The estimated compound half-life was 5.8 to 8.1 days. These were hormone measurements after study administration in healthy volunteers.
A companion experiment in healthy men found preserved pulsatile secretion. A further study of eleven healthy young men detected serum-protein changes correlated with IGF-1. Together, these papers make a convincing case that the GH/IGF-1 axis responded. Claims of better sleep, recovery or longevity leave me unconvinced here; the cited studies did not establish those clinical benefits.
There is also a striking growth-restoration result in mice unable to make GHRH. The genetic absence of the hormone defines that animal experiment. It gives a precise biological reason for the response, and very different starting conditions from those of a healthy adult pursuing a fitness goal.
Circulation beyond the trials
An analytical study identified CJC-1295 in an unknown seized preparation. That is a revealing kind of success: a laboratory could determine the substance's identity while the programme needed to establish a medical use remained unfinished.
Community descriptions of deeper sleep, less soreness, a leaner appearance and more energy are anecdotal reports rather than clinical evidence. Puffiness, tingling hands, local reactions, flushing and fatigue appear in the same discussions. Combination use and confusion over DAC make their attribution particularly difficult.
The original long-acting development programme was discontinued. CJC-1295 has no approved human use anywhere, no large long-term safety trials in healthy adults, and a prohibition at all times in sport under WADA Section S2. The halted programme makes CJC-1295's clinical ambitions too uncertain for my confidence.
Prolonged exposure and safety
Growth-hormone-axis stimulation brings concerns about fluid retention, nerve compression and insulin sensitivity. Sustained IGF-1 elevation also raises a theoretical cancer question; population associations between higher IGF-1 and some cancers do not establish that CJC-1295 causes them. The GHRH-analogue review is useful context for these pharmacological questions.
FDA's 2024 Pharmacy Compounding Advisory Committee materials cited immunogenicity and other safety concerns as part of the basis for not recommending CJC-1295 for the 503A compounding bulks list. This site offers no human dosing protocol. Prolonging a signal is a chemical capability; establishing a worthwhile and acceptably safe use takes a clinical programme.
The semaglutide trials offer an illuminating neighbouring history: albumin binding followed by completed trials with clinical outcomes. Their success remains attached to semaglutide and the populations actually studied.